David A. Braun, MD, PhD, shares his takeaways from the network meta-analysis on lenvatinib plus pembrolizumab in advanced RCC, and Martin H. Voss, MD, discusses outcomes with cabozantinib following frontline lenvatinib plus pembrolizumab.
FDA Accepts BLA for Subcutaneous Nivolumab in Advanced or Metastatic Solid Tumors
Merkow and Connell Highlight Considerations for HAI Pump Use in CRC
Early Responses With CTX130 Renew Hope for Anti-CD70 CAR T-Cell Therapy in Advanced RCC
Bou Farhat and Nassar on the Use of NGS Mutation Signature vs IHC for Identifying dMMR Tumors
State of the Science Summit - Hematologic Malignancies: Chaired by Minoo Battiwalla, MD, MS
Applying ASCO GU 2024 Data to Clinical Practice in Bladder, RCC Care
Time to Bladder Cancer Treatment Is Similar Among Black and White Patients, But Other Disparities Persist
Dr Jia on the Evolving Role of Metastasis-Directed Radiotherapy in Prostate Cancer
Dr Wang on the Limited Utility of Quantitative Molecular Imaging Thresholds in RCC
Darolutamide Use Is Routine in Both Doublets and Triplet Therapies in mHSPC